Argus downgrades Abbott Laboratories (NYSE: ABT) from Buy to Hold, citing competitive pressures.

The firm states, "While we are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE